Skip to main content
. 2023 Sep 27;15(19):4746. doi: 10.3390/cancers15194746

Figure 1.

Figure 1

Pictorial scheme of the available ligands (comet nucleus) and isotopes (comet tails) with application to prostate cancer management. PSMA is the only theragnostic compound.